Advertisement
Advertisement
U.S. markets open in 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tenax Therapeutics, Inc. (TENX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1470+0.0048 (+3.38%)
At close: 04:00PM EST
0.1395 -0.01 (-5.10%)
Pre-Market: 08:02AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.1422
Open0.1480
Bid0.1331 x 1000
Ask0.1395 x 1000
Day's Range0.1300 - 0.1480
52 Week Range0.0800 - 1.4590
Volume2,114,818
Avg. Volume4,526,415
Market Cap6.57M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.4920
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TENX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Tenax Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Zacks Small Cap Research

    TENX: Agility Required to Unlock Considerable Upside

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Update on Tenax Tenax Therapeutics, Inc. (NASDAQ:TENX) will delay the start of its Phase III clinical trials for levosimendan and imatinib for the treatment of pulmonary arterial hypertension (PAH) until 2023, pending funding. The share price has been under pressure for some time and there is insufficient capitalization to

  • GlobeNewswire

    Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan. The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extens

  • Benzinga

    Tenax Therapeutics Stock Jumps On Strategic Alternative Review

    Tenax Therapeutics Inc (NASDAQ: TENX) is evaluating alternative strategic paths. Roth Capital Partners will support Tenax Therapeutics as its financial advisor in this process. Tenax Therapeutics and its Board of Directors believe the company's current valuation does not accurately reflect the potential value of its clinical-stage pipeline. Tenax Therapeutics is developing two Phase 3 ready assets - TNX-201 (modified release imatinib) for pulmonary arterial hypertension (PAH) and TNX-103 (oral l

Advertisement
Advertisement